|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Retrospective analysis of extra-gastrointestinal stromal tumors显示文摘AIM:To investigate the clinicopathologic features of patients with extra-gastrointestinal stromal tumors(EGISTs)in South Korea.METHODS:A total of 51 patients with an EGIST were identified.The clinicopathologic features,including sex,age,location,tumor size,histology,mitotic rate,immunohistochemical features,genetic status and survival data,were analyzed.RESULTS:The median age was 55 years(range:29-80years),and male:female ratio was 1:1.04.The most common site was in the mesentery(n=15)followed by the retroperitoneum(n=13)and omentum(n=8).The median tumor size was 9.0 cm(range:2.6-30.0cm)and the median mitotic rate was 5.0/50HPF.(1/50-185/50).KIT was analyzed in 16,which revealed 10cases with wild-type KIT and 6 cases with an exon 11mutation.Among 51 patients,31 patients had undergone surgery,and 10 had unresectable disease and had taken palliative imatinib,which resulted in 22.7 mo of progression-free survival.Of the patients who had undergone surgery,18 did not take adjuvant imatinib,and 8 of these were categorized as'high risk'according to the risk criteria.However,the relapse-free survival was not different(P=0.157)between two groups.CONCLUSION:Because the biologic behaviors of GISTs differ according to the location of the tumor,a more stratified strategy is required for managing EGISTs including incorporation of molecular features. | Jun Ho Yi Byeong-Bae Park Jung Hun Kang In Gyu Hwang Dong Bok Shin Sun Jin Sym Hee Kyung Ahn Soon Il Lee Do Hyoung Lim Keon Woo Park Young-Woong Won Sung Hee Lim Se Hoon Park | 2015 | World Journal of Gastroenterology2015，21，6： | 9 |
| 2 | 健康男性的胰岛素抵抗指数、肥胖、血清PSA水平间的关系显示文摘本研究旨在确定血清PSA水平低于4ngmL^-1的健康男性的胰岛素抵抗指数、肥胖和血清前列腺特异性抗原(PSA)水平之间的关系。调查对象为韩国水力原子力株式会社的11827名健康男性职员,在2003年1月到2008年12月间接受了体检,体检项目包括空腹血糖水平、空腹胰岛素水平和血清PSA水平。用稳态模式评估法(HOMA;[空腹血糖水平×空腹胰岛素水平]/22.5)和定量胰岛素敏感性检验指数(QUICKI;1/[10g(空腹胰岛素水平)+log(空腹血糖水平)])测定胰岛素抵抗指数。协方差分析(ANOVA)和Duncan’s多重比较试验显示,随着用HOMA和OuICKI测定的胰岛素抵抗指数四分位的上升,年龄标化体重指数(BMI)也显著增加(P〈0.001)。多变量线性回归分析表明,相对于血清PSA水平,年龄、BMI、以及用HOMA或QUICKI测得的胰岛素抵抗指数都是显著的独立变量(P〈0.001)。本研究说明胰岛素抵抗指数和BMI都是血清PSA水平的独立变量,在健康男性体内,两者都与血清PSA水平呈负相关,两者之间呈正相关。 | June Hyun Han Yong Taec Lee Kyung Won Kwak Seung Hyun Ahn In Ho Chang Soon Chul Myung Seung Young Oh Yong-Seong Lee Wonyong Kim Young-Woo Jin Tae-In Choi Sook Hee Sung | 2010 | Asian Journal of Andrology2010，12，3： | 2 |
| 3 | 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的Ⅱ期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11)显示文摘背景与目的一项比较艾日布林联合吉西他滨(eribulin plus gemcitabine,EG)或紫杉醇联合吉西他滨(paclitaxel plus gemcitabine,PG)作为转移性乳腺癌(metastatic breast cancer,MBC)患者一线化疗方案的II期临床试验发现,EG方案的神经毒性较低,但疗效与PG方案相似。在本研究中,我们分析了该临床实验中的癌症患者生命质量测评量表–紫杉烷(functional assessment of cancer therapy-taxane,FACT-Taxane)问卷评分以确定他们的生活质量(quality of life,QoL)。方法使用韩国版的FACT-Taxane问卷评估QoL。在评估基线之后,前12个疗程中每2个疗程评估1次QoL,之后每3个疗程评估1次QoL。使用线性混合模型评估EG组和PG组QoL的差异。结果在118例入组患者中,117例在基线时回复了FACT-Taxane问卷,PG组中有1例患者没有回复。EG组和PG组之间的基线QoL评分没有差异。在治疗期间,除了第11个疗程外,在第2–13个化疗疗程后,PG组紫杉烷亚量表评分显著高于EG组(均P<0.05)。神经病变特异性分析显示PG组患者的神经病症状比EG组患者更早出现且更严重(P<0.001)。结论在我们的QoL分析中,与PG方案相比,EG方案延迟并减少神经病变的发生。因此,艾日布林是MBC一线化疗药物紫杉醇的合理替代品。 | Ji‑Yeon Kim Seri Park Seock‑Ah Im Sung‑Bae Kim Joohyuk Sohn Keun Seok Lee Yee Soo Chae Ki Hyeong Lee Jee Hyun Kim Young‑Hyuck Im Tae‑Yong Kim Kyung‑Hun Lee Jin‑Hee Ahn Gun Min Kim In Hae Park Soo Jung Lee Hye Sook Han Se Hyun Kim Kyung Hae Jung Yeon Hee Park Korean Cancer Study Group | 2019 | 癌症2019，38，8： | 2 |
| 4 | Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma显示文摘AIM: To assess the efficacy and safety of weekly docetaxel plus a fixed-dose rate(FDR) of gemcitabine in metastatic esophageal squamous cell carcinoma(SCC).METHODS: A multi-center, open-label, prospective phase Ⅱ study was designed.Thirty-three esophageal SCC patients with documented progression after fluoropyrimidine/platinum-based first-line chemotherapy were enrolled and treated with docetaxel 35 mg/m2 and gemcitabine 1000 mg/m2 iv at a FDR(10 mg/m2 per minute) on days 1 and 8.Treatment was repeatedevery twenty-one days until disease progression, unacceptable toxicity, or consent withdrawal.The primary endpoint was response rate(RR), and secondary endpoints were safety, progression-free survival(PFS) and overall survival(OS).RESULTS: Combination of weekly docetaxel and FDR gemcitabine was well tolerated: the most common treatment-related adverse events were anemia(97%), fatigue(64%) and neutropenia(55%).One patient with multiple lung and lymph node metastases died of respiratory failure after receiving four cycles of chemotherapy, and the possibility of drug-induced pneumonitis could not be completely excluded.Disease control(objective response plus stable disease) in the ITT population was achieved in 88% of patients, and the overall RR was 30%(95%CI: 15%-46%).The median PFS and OS were 4.0(95%CI: 3.4-4.6) and 8.8 mo(95%CI: 7.8-9.8 mo), respectively.CONCLUSION: A combination of weekly docetaxel and FDR gemcitabine showed promising antitumor activity and tolerability in previously treated, metastatic esophageal SCC. | Min-Young Lee Ki Sun Jung Hae Su Kim Ji Yun Lee Sung Hee Lim Moonjin Kim Hyun Ae Jung Sung Min Kim Jong Mu Sun Myung-Ju Ahn Jeeyun Lee Se Hoon Park Seong Yoon Yi In Gyu Hwang Sang-Cheol Lee Hee Kyung Ahn Do Hyoung Lim Soon Il Lee Keon Woo Park | 2015 | World Journal of Gastroenterology2015，21，14： | 2 |
| 5 | A Randomized, Multi-Center, Clinical Trial to Assess the Efficacy and Safety of Alginate Carboxymethylcellulose Hyaluronic Acid Compared to Carboxymethylcellulose Hyaluronic Acid to Prevent Postoperative Intrauterine Adhesion显示文摘 | Tak Kim Ki Hoon Ahn Doo Seok Choi Kyung Joo Hwang Byoung Ick Lee Min Hyung Jung Jae Weon Kim Jong Hyuk Kim Sun Hee Cha Ki Hwan Lee Kyu Sup Lee Sung Tack Oh Chi Heum Cho Jeong Ho Rhee | 2012 | The Journal of Minimally Invasive Gynecology2012，，6： | 1 |
| 6 | Quality of life outcomes including neuropathy-associated scale from a phase II,multicenter,randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer:Korean Cancer Study Group Trial(KCSG BR13-11)显示文摘Background: A phase II clinical trial of the comparison between eribulin plus gemcitabine (EG) and paclitaxel plus gemcitabine (PG) as first-line chemotherapy for patients with metastatic breast cancer (MBC) found that the EG regimen was less neurotoxic, but was similar in efficacy to the PG regimen. In the present study, we analyzed functional assessment of cancer therapy-taxane (FACT-Taxane) questionnaires from patients in this clinical trial to determine their quality of life (QoL). Methods: QoL was assessed using the Korean version of the FACT-Taxane questionnaires. After baseline assessment, QoL was assessed every 2 cycles for 12 cycles and every 3 cycles thereafter. The linear mixed model was used to evaluate the difference in QoL between the EG and PG arms. Results: Of the 118 enrolled patients, 117 responded to the FACT-Taxane questionnaires at baseline, 1 in the PG arm did not. Baseline QoL scores were not different between the EG and PG arms. During treatment, taxane subscale scores were significantly higher in the PG arm than in the EG arm after 2-13 cycles of chemotherapy (all P < 0.05), except for the 11th cycle. Neuropathy-specific analysis showed that patients in the PG arm had earlier and more severe neuropathic symptoms than those in the EG arm (P < 0.001). Conclusions: In our QoL analysis, the EG regimen delayed and decreased neuropathy as compared with the PG regimen. Therefore, eribulin would be a reasonable substitute for paclitaxel as first-line chemotherapy for MBC. | Ji-Yeon Kim Seri Park Seock-Ah Im Sung-Bae Kim Joohyuk Sohn Keun Seok Lee Yee Soo Chae Ki Hyeong Lee Jee Hyun Kim Young-Hyuck Im Tae-Yong Kim Kyung-Hun Lee Jin-Hee Ahn Gun Min Kim In Hae Park Soo Jung Lee Hye Sook Han Se Hyun Kim Kyung Hae Jung Yeon Hee Park Korean Cancer Study Group | 2019 | Cancer Communications2019，39，1： | 1 |
| 7 | Extraosseous osteosarcoma:Single institutional experience in Korea 显示文摘 | Soohyeon LEE Mi Rae LEE Su Jin LEE Hee Kyung AHN Junho YI Seong Yoon YI | 2010 | Asia-Pacific Journal of Clinical Oncology2010，6，： | 1 |
| 8 | Microarray Gene Expression Profiling for Predicting Complete Response to Preoperative Chemoradiotherapy in Patients with Advanced Rectal Cancer显示文摘 | Il-Jin Kim Ph.D. Seok-Byung Lim M.D. Hio Chung Kang Ph.D. Hee Jin Chang M.D. Sun-A Ahn B.S. Hye-Won Park M.S. Sang-Geun Jang B.S. Jae-Hyun Park M.S. Dae Yong Kim M.D. Kyung Hae Jung M.D. Hyo Seong Choi M.D. Seung-Yong Jeong M.D. Dae Kyung Sohn M.D. Duck-W | 2007 | Diseases of the Colon & Rectum2007，，9： | 1 |
| 9 | A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer显示文摘 | Young Saing Kim Sun Jin Sym Se Hoon Park Inkeun Park Junshik Hong Hee Kyung Ahn Jinny Park Eun Kyung Cho Woon Ki Lee Min Chung Jae Hoon Lee Dong Bok Shin | 2014 | Cancer Chemotherapy and Pharmacology2014，，1： | 1 |
| 10 | Clinical significance of the BRAF V600E mutation in multifocal papillary thyroid carcinoma in Korea显示文摘 | Hwa Young Ahn Yun Jae Chung Byung Seup Kim Kyung Ho Kang Ju Won Seok Hee Sung Kim Sung Jun Park Bo Youn Cho | 2013 | Surgery2013，，： | 1 |
| 11 | The osteogenic differentiation of rat muscle-derived stem cells in vivo within in situ -forming chitosan scaffolds显示文摘 | Kyung Sook Kim Jung Hwa Lee Hyun Hee Ahn Ju Young Lee Gilson Khang Bong Lee Hai Bang Lee Moon Suk Kim | 2008 | Biomaterials2008，，33： | 1 |
| 12 | Preoperative serum tissue polypeptide‐specific antigen is a valuable prognostic marker in breast cancer显示文摘 | Soo Kyung Ahn Hyeong‐Gon Moon Eunyoung Ko Han Suk Kim Hee‐Chul Shin Jisun Kim Jee Man You Wonshik Han Dong‐Young Noh | 2012 | Int J Cancer2012，，4： | 1 |
| 13 | Investigation of the mechanical behavior of a flexible solid metal seal for a cryogenic butterfly valve 显示文摘 | Jun Tae Ahn Kyung Chul Lee Kwon Hee Lee | 2011 | Journal of Mechanical Science and Technology2011，25，9： | 1 |
| 14 | Lymph Node Ratio as a Prognostic Factor in Patients With Stage III Rectal Cancer Treated With Total Mesorectal Excision Followed by Chemoradiotherapy显示文摘 | Young Seok Kim Jong Hoon Kim Sang Min Yoon Eun Kyung Choi Seung Do Ahn Sang-wook Lee Jin Cheon Kim Chang Sik Yu Hee Chul Kim Tae Won Kim Heung Moon Chang | 2009 | International Journal of Radiation Oncology Biology Physics2009，，3： | 1 |
| 15 | Lymph Node Ratio as a Prognostic Factor in Patients With Stage III Rectal Cancer Treated With Total Mesorectal Excision Followed by Chemoradiotherapy显示文摘 | Young Seok Kim Jong Hoon Kim Sang Min Yoon Eun Kyung Choi Seung Do Ahn Sang-wook Lee Jin Cheon Kim Chang Sik Yu Hee Chul Kim Tae Won Kim Heung Moon Chang | 2009 | International Journal of Radiation Oncology, Biology, Physics2009，，3： | 1 |
| 16 | Synthesis of manganese substituted hexaaluminate and its fabrication into monolithic honeycombs for catalytic combustion 显示文摘 | Moon Hee Han Young Soo Ahn Si Kyung Kim | 2001 | Materials Science and Engineering A2001，，302： | 1 |
| 17 | Synthesis of manganese substituted hexaaluminate and its fabrication into monolithic honeycombs for catalytic combustion显示文摘 | Moon Hee Han Young Soo Ahn Si Kyung Kim | 2001 | Materials Science and Engineering A2001，302，： | 1 |
| 18 | P21-Activated Kinase 4 Overexpression in Metastatic Gastric Cancer Patients显示文摘 | Hee Kyung Ahn Jiryeon Jang Jeeyun Lee Hoon Park Se Joon Oh Park Young Suk Park Ho Yeong Lim Kyoung-Mee Kim Won Ki Kang | 2011 | Translational Oncology2011，，： | 1 |
| 19 | Comparison of clinical outcomes between culprit vessel only and multivessel percutaneous coronary intervention for ST-segment elevation myocardial infarction patients with multivessel coronary diseases显示文摘为圣片断举起的完全的 revascularization 的 BackgroundThe 临床的意义心肌的梗塞(STEMI )病人没有心脏性的吃惊,仍然在承认期间是从有 multivessel 疾病的朝鲜心肌的梗塞登记的 1406 个 STEMI 病人全部的 debatable.MethodsA 经历了主要经皮的冠的干预( PPCI )的人,被分析。我们使用了匹配的倾向分数(PSM ) 控制在犯人之间的基线特征的差别仅仅干预(CP ) 和 multivessel 经皮的冠的干预(MP ) ,并且在两倍容器疾病(DVD ) 和三倍的容器疾病(TVD ) 之间。在 discharge.ResultsTVD 病人显示出向的更高的发生以后,主要不利心脏的事件(向)被分析一年(14.2%对8.6%, P = 0.01 ), revascularization 的任何原因(10.6%对5.9%, P = 0.01 ),并且重复一种总线标准(9.5%对5.7%, P = 0.02 ),作为与 DVD 病人相比在一年在以后期间排出。 MP 有效地减少了向(7.3%对13.8%, P = 0.03 )与为死亡的一年,而是所有原因的 CP 相比(1.6%对3.2%, P = 0.38 ), MI (0.4%对0.8%, P = 1.00 ),并且 revascularization 的任何原因(5.3%对9.7%, P = 0.09 )在有 TVD 的病人更高显示出的二治疗 groups.ConclusionsSTEMI 是可比较的向的率,同样与 DVD 相比。MP 表现在 PPCI 期间或在为没有心脏性的吃惊的 STEMI 病人的承认期间特定在这个大放大数据库的向的显示出的更低的率。因此,没有心脏性的吃惊, MP 能为 STEMI 病人被看作一种有效治疗选择。 | Kwang Sun Ryu Hyun Woo Park Soo Ho Park Ho Sun Shon Keun Ho Ryu Dong Gyu Lee Mohamed EA Bashir Ju Hee Lee Sang Min Kim Sang Yeub Lee Jang Whan Bae Kyung Kuk Hwang Dong Woon Kim Myeong Chan Cho Young Keun Ahn Myung Ho Jeong Chong Jin Kim Jong Seon Park Young Jo Kim Yang Soo Jang Hyo Soo Kim Ki Bae Seung | 2015 | Journal of Geriatric Cardiology2015，12，3： | 1 |
| 20 | Investigation of the mechanical behavior of a flexible solid melal seal for a cryogenie butterfly valve 显示文摘 | Jun Tae Ahn Kyung Chul Lee Kwon Hee Lee ct al | 2011 | Journal of Mechanical Science and Technology2011，25，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员